J Korean Diabetes.  2021 Jun;22(2):91-96. 10.4093/jkd.2021.22.2.91.

Dipeptidyl Peptidase 4 Inhibitor, an Update

• Lee JH

• KMID: 2526186
• DOI: http://doi.org/10.4093/jkd.2021.22.2.91

Abstract

Dipeptidyl peptidase 4 (DPP4) inhibitors, one of the most prescribed second-line antidiabetic drugs in South Korea, have been available since 2006. Many studies focusing on the safety profiles of DPP4 inhibitors have been reported. DPP4 inhibitors were associated with a small increased incidence of acute pancreatitis in placebo-controlled trials, although most observational studies did not support this hypothesis. There were no significant differences in major cardiovascular events in a large prospective cardiovascular outcomes trial with DPP4 inhibitors, although a higher risk of hospitalization for heart failure was reported with saxagliptin. Additionally, the safety data of DPP4 inhibitors for diabetes management during the coronavirus disease-19 (COVID-19) pandemic have been provided recently.

Keyword

COVID-19; Diabetes mellitus; type 2; Dipeptidyl-peptidase IV inhibitors; Heart failure; Pancreatitis